8-K: Champions Oncology Reports Record Q2 Service Revenue

Champions Oncology announced its second quarter fiscal 2026 financial results, reporting an 11% increase in total revenue to $15 million and record quarterly service revenue.

Summary

• Total revenue for the second quarter of fiscal 2026 increased 11% to $15.0 million compared to $13.5 million in the same period last year.
• Oncology services profit for Q2 FY2026 was $7.8 million, with an oncology services margin of 52%, up from 45% in the prior year.
• Net income for Q2 FY2026 was $237,000, a decrease from $728,000 in Q2 FY2025.
• Adjusted EBITDA for Q2 FY2026 was $843,000, down from $1.1 million in Q2 FY2025.
• Total revenue for the first half of fiscal 2026 increased 5% to $29.0 million compared to $27.6 million in the prior year period.
• The company reported a net loss of $230,000 for the first half of fiscal 2026, compared to a net income of $2.1 million in the first half of fiscal 2025.
• Adjusted EBITDA for the first half of fiscal 2026 was $962,000, down from $3.2 million in the first half of fiscal 2025.
• The company ended the quarter with approximately $8.5 million in cash and no debt.
• Net cash used in operating activities was approximately $1.9 million for the three months ended October 31, 2025, primarily driven by an increase in accounts receivable and a decline in deferred revenue.

Sentiment

Score: 6

Explanation: While revenue growth and margin improvement are positive, the significant decline in net income and adjusted EBITDA for both the quarter and year-to-date, coupled with increased operating expenses and negative cash flow from operations, indicates underlying challenges. However, management's confidence in future growth, strategic investments, and positive full-year guidance provide a balanced, cautiously optimistic outlook.

Positives

• Record quarterly service revenue was achieved at $14.9 million.
• Total revenue increased 11% in Q2 FY2026 to $15.0 million and 5% in H1 FY2026 to $29.0 million, demonstrating continued top-line growth.
• Oncology services margin improved significantly to 52% in Q2 FY2026 from 45% in Q2 FY2025, driven by higher revenue and operational efficiencies, including lower outsourced lab service costs.
• The company maintains a strong balance sheet with approximately $8.5 million in cash and no debt as of October 31, 2025.
• Management is cautiously optimistic about a strengthening pharma and biotech funding environment, which is expected to support improved bookings in calendar 2026.
• Strategic investments in the data platform and a strengthened business development organization are expected to contribute meaningfully to long-term growth.

Negatives

• Net income decreased significantly to $237,000 in Q2 FY2026 from $728,000 in Q2 FY2025.
• Adjusted EBITDA decreased to $843,000 in Q2 FY2026 from $1.1 million in Q2 FY2025.
• The company reported a net loss of $230,000 for the first half of fiscal 2026, compared to a net income of $2.1 million in the prior year period.
• Adjusted EBITDA for the first half of fiscal 2026 decreased substantially to $962,000 from $3.2 million in the prior year period.
• Total costs and operating expenses increased by 16.4% in Q2 FY2026 and 15.2% in H1 FY2026, primarily due to increased R&D, sales & marketing, and general & administrative expenses.
• Net cash used in operating activities was approximately $1.9 million for Q2 FY2026 and $(1.135) million for the first half of fiscal 2026, primarily due to an increase in accounts receivable and a decline in deferred revenue.

Risks

• Forward-looking statements inherently involve risk and uncertainties, and actual results could differ materially from anticipated outcomes due to unforeseen factors.
• The company's future results, levels of activity, performance, or achievements may not meet expectations.
• The data business, while expected to contribute to long-term growth, introduces additional variability in shorter reporting periods.
• The company refers to its Form 10-K for the fiscal year ended April 30, 2025, for a discussion of specific risks, uncertainties, and other factors.

Future Outlook

The company remains on track to deliver year-over-year revenue growth and achieve positive adjusted EBITDA for the full fiscal year. Management is cautiously optimistic about a strengthening pharma and biotech funding environment, which is expected to support improved bookings as the company moves into calendar 2026. Strategic investments in the data platform are anticipated to contribute meaningfully to long-term growth, and the transition of radiolabeling work into internal labs over the coming quarters is expected to reduce cost of sales and improve oncology services margin.

Management Comments

• "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress." Robert Brainin, CEO
• "While our business can vary period to period, we manage and evaluate performance primarily on an annual basis and remain focused on delivering sustainable year-over-year revenue growth." Robert Brainin, CEO
• "We continue to be cautiously optimistic that the pharma and biotech funding environment is beginning to strengthen, which should support improved bookings as we move into calendar 2026." Robert Brainin, CEO
• "In parallel with our core services business, we continued to invest in our data platform—expanding its capabilities to provide greater value to our pharma partners—and strengthened our business development organization to support adoption of these offerings." Robert Brainin, CEO
• "As our data business scales, we expect it to contribute meaningfully to long-term growth, even as it introduces additional variability in shorter reporting periods." Robert Brainin, CEO
• "From a financial standpoint, the period reflected continued progress in our operating model." David Miller, CFO
• "Oncology services margin improved as higher revenue was generated on a largely stable cost base, highlighting the leverage in our business as volumes increase." David Miller, CFO
• "Operating expenses rose as planned, reflecting targeted investments in areas that support future growth, particularly within our data platform and related infrastructure." David Miller, CFO
• "Based on our year-to-date performance and current visibility, we remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year." David Miller, CFO
• "We believe the combination of disciplined cost control and targeted strategic investment positions the Company for continued improvement as market conditions strengthen." David Miller, CFO

Industry Context

The company operates in the translational oncology research sector, providing services and data platforms to biopharma organizations. Management's cautious optimism regarding a strengthening pharma and biotech funding environment suggests that the broader industry may be recovering from a period of tighter capital, which could lead to increased demand for preclinical and clinical research services. The investment in a data platform aligns with a trend towards data-driven drug discovery and development in the biopharma industry, indicating the company is adapting to evolving market needs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for direct assessment.
• The company's oncology services margin of 52% in Q2 FY2026 indicates strong operational efficiency within its specific service offerings, but a direct comparison to industry averages without more context is not possible from this filing.
• The statement about the pharma and biotech funding environment beginning to strengthen suggests that the company's performance is influenced by broader industry capital availability, which impacts R&D spending by its clients, aligning with general industry sentiment regarding funding cycles.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic investments and anticipated return to full-year profitability, but short-term profitability metrics (net income, adjusted EBITDA) have declined, which could impact investor sentiment.
• Employees: Increased compensation expenses in sales & marketing and general & administrative, along with investments in R&D, suggest continued hiring and investment in human capital, particularly for the data platform and business development.
• Customers (Biopharma Organizations): Continued investment in the data platform and expanded capabilities aim to provide greater value, potentially strengthening customer relationships and attracting new clients.
• Suppliers: Lower outsourced lab service costs in Q2 suggest a shift in supplier reliance or improved negotiation, while the planned transition of radiolabeling work in-house will impact external lab service providers.

Next Steps

• Continue to deliver year-over-year revenue growth for the full fiscal year.
• Achieve positive adjusted EBITDA for the full fiscal year.
• Monitor and benefit from the strengthening pharma and biotech funding environment, aiming for improved bookings in calendar 2026.
• Scale the data business to contribute meaningfully to long-term growth.
• Transition radiolabeling work into internal labs over coming quarters to reduce cost of sales and improve oncology services margin.
• Host a conference call on December 15, 2025, at 4:30 p.m. EST to discuss results.
• File Form 10-Q on December 15, 2025, for full financial details.

Key Dates

Recommendation

While Champions Oncology reported strong revenue growth and improved oncology services margin, the significant decline in net income and adjusted EBITDA for both the quarter and year-to-date, coupled with negative cash flow from operations, presents a mixed financial picture. The company's strategic investments in its data platform and business development, along with management's optimistic outlook for full-year revenue growth and positive adjusted EBITDA, suggest potential for future improvement. However, the short-term profitability challenges and increased operating expenses warrant a cautious approach. A "hold" recommendation allows investors to observe if the strategic investments translate into sustained profitability and if the strengthening pharma/biotech funding environment materializes into improved bookings and financial performance in the coming quarters, without taking on additional risk or divesting based on current mixed signals.

Keywords

Oncology Research, Translational Oncology, Biopharma Services, Cancer Research, Preclinical Services, Clinical Research, Patient-Derived Xenograft, PDX Models, Data Platform, Biotech Funding, Financial Results, SEC Filing, CSBR